Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142939 | 1.00 | CHRM2 (0.59) | CHRM2CHRM1CHRM3TAAR1HDAC1 | |
| SCHEMBL3689085 | 0.93 | CHRM2 (0.63) | CHRM2CHRM1CHRM3TAAR1HDAC1 | |
| SCHEMBL21002124 | 0.91 | TAAR1 (0.69) | CHRM2CHRM1CHRM3TAAR1HDAC1 | |
| SCHEMBL21002162 | 0.89 | TAAR1 (0.71) | CHRM2CHRM1CHRM3TAAR1HDAC1 | |
| SCHEMBL12630196 | 0.86 | SIGMAR1 (0.66) | CHRM2CHRM1CHRM3TAAR1HDAC1 | |
| SCHEMBL5315445 | 0.85 | TAAR1 (0.67) | CHRM2CHRM1CHRM3TAAR1IDO1 | |
| SCHEMBL21002016 | 0.85 | TAAR1 (0.71) | CHRM2CHRM1CHRM3TAAR1HDAC1 | |
| SCHEMBL29986862 | 0.85 | TAAR1 (0.71) | CHRM2CHRM1CHRM3TAAR1HDAC1 | |
| SCHEMBL9796229 | 0.84 | PPARG (0.61) | CHRM2CHRM1CHRM3TAAR1HDAC1 | |
| SCHEMBL10534527 | 0.84 | PPARG (0.61) | CHRM2CHRM1CHRM3TAAR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476302-B2 | α-ketoamide derivatives useful endothelial lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-02 | — | — | US | claimed |
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | LIPG, LIPA, LIPE | CHRM2 3131/4885CHRM1 3681/4885CHRM3 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.